A phase I/II trial evaluating galinpepimut-S in combination with KEYTRUDA in five cancer indications

Trial Profile

A phase I/II trial evaluating galinpepimut-S in combination with KEYTRUDA in five cancer indications

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Galinpepimut S (Primary) ; Pembrolizumab (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Ovarian cancer; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2017 New trial record
    • 02 Oct 2017 This trial is expected to be initiated in 1H 2018, according to a SELLAS Life Sciences Group media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top